<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01941576</url>
  </required_header>
  <id_info>
    <org_study_id>SJTUMS-20130903</org_study_id>
    <nct_id>NCT01941576</nct_id>
  </id_info>
  <brief_title>Effects of rhBNP in Pediatrics After Corrective Repair of Tetralogy Of Fallot</brief_title>
  <official_title>Effects of rhBNP in Pediatrics After Corrective Repair of Tetralogy Of Fallot</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects of rhRNP on urine output and&#xD;
      hemodynamics following corrective repair of Tetralogy Of Fallot.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CVP(central venous pressure) and cardiac output are serious index in children with Tetralogy&#xD;
      Of Fallot after the corrective repair.The purpose of this study is to investigate if the&#xD;
      therapy of rhRNP can improve the survival and life quality after the corrective repair of&#xD;
      Tetralogy Of Fallot.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2013</start_date>
  <completion_date type="Actual">July 20, 2019</completion_date>
  <primary_completion_date type="Actual">December 31, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from Baseline in BNP and CVP after the infusion of rhBNP</measure>
    <time_frame>12 months after operation of Tetralogy Of Fallot</time_frame>
    <description>we will evaluate the cardiac function through the consecutive changed numerical value of brain natriuretic peptide and Central Venous Pressure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline on the volume of urine out and numerical value of serum creatinine and blood urea nitrogen</measure>
    <time_frame>12 months after operation of Tetralogy Of Fallot</time_frame>
    <description>we evaluate the renal function through the volume of urine out and numerical value of serum creatinine and blood urea nitrogen.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Congenital Heart Defects</condition>
  <condition>Tetralogy Of Fallot</condition>
  <arm_group>
    <arm_group_label>rhBNP Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients after corrective repair of Tetralogy Of Fallot will be treat with routinely therapy, including inotropics and diuretics, combined a rhBNP infusion 24 hours after operation. The dose of recombinant human brain natriuretic peptide (rhBNP) will be 1.5 mcg/kg for loading, followed by continuous infusion recombinant human brain natriuretic peptide 0.01-0.01mcg/kg/min for 72 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients after corrective repair of Tetralogy Of Fallot will be treat with routinely therapy, including inotropics and diuretics, combined a placebo infusion 24 hours after operation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>recombinant human brain natriuretic peptide (rhBNP)</intervention_name>
    <description>Patients are first given a loading dose of recombinant human brain natriuretic peptide (rhBNP) 1.5 mcg/kg, followed by continuous infusion recombinant human brain natriuretic peptide 0.01-0.01mcg/kg/min for 72 hours.</description>
    <arm_group_label>rhBNP Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (0.9% sodium chloride)</intervention_name>
    <description>Patients after corrective repair of Tetralogy Of Fallot will be treat with routinely therapy, including inotropics and diuretics, combined a placebo infusion 24 hours after operation.</description>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent obtained from patient's legally acceptable representative.&#xD;
&#xD;
          -  Pediatric patients after Repair of Tetralogy Of Fallot.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Psychotic, addictive or other disorder limiting the ability to provide informed&#xD;
             consent or to comply with study requirements.&#xD;
&#xD;
          -  Treatment or planned treatment with another investigational drug within 3 months of&#xD;
             screening.&#xD;
&#xD;
          -  Known hypersensitivity to bosentan or any of the excipients&#xD;
&#xD;
          -  cardiogenic shock and inclination of hypotension（SBP&lt; 60mmHg）.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhuoming Xu, MD,PhD</last_name>
    <role>Study Director</role>
    <affiliation>Shanghai Children's Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiac intensive care unit, Department of cardiothoracic vascular surgery, Shanghai Children's Medical Center, Medical college of Shanghai Jiaotong University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 3, 2013</study_first_submitted>
  <study_first_submitted_qc>September 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2013</study_first_posted>
  <last_update_submitted>October 26, 2020</last_update_submitted>
  <last_update_submitted_qc>October 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Xu Zhuoming</investigator_full_name>
    <investigator_title>Vice Chief, Department of thoracic and cardiovascular surgery</investigator_title>
  </responsible_party>
  <keyword>Heart defects, Congenital</keyword>
  <keyword>rhBNP</keyword>
  <keyword>heart failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Defects, Congenital</mesh_term>
    <mesh_term>Tetralogy of Fallot</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Natriuretic Peptide, Brain</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

